The FDA is reconsidering its decision to ban compounding pharmacies from supplying cheaper versions of Eli Lilly’s blockbuster weight loss and diabetes drugs, Mounjaro and Zepbound. This comes after a lawsuit filed by compounding groups challenging the FDA’s restriction. Eli Lilly has also issued cease-and-desist letters to companies offering similar products, citing potential safety concerns.